Infective Endocarditis: A Comprehensive Review

Infective endocarditis is an inflammatory disease characterized by infection of the endocardial surface of the heart. Despite advancements in diagnostic and therapeutic techniques, the disease remains challenging due to its heterogeneous clinical presentation and severe complications. The incidence of IE is estimated to be 3 to 10 cases per 100,000 person-years, with a higher prevalence among older adults, intravenous drug users, and individuals with underlying cardiac conditions. The disease carries a high risk of systemic embolization, heart failure, and mortality if not promptly diagnosed and treated. This article provides a comprehensive review of infective endocarditis, highlighting the need for a multidisciplinary approach in its management.

Etiology and Risk Factors: Infective endocarditis is predominantly caused by bacterial pathogens, though fungal and other microbial agents may also be implicated. Staphylococcus aureus is the leading causative organism, particularly in healthcare-associated infections and intravenous drug users. Viridans group streptococci, Enterococci, and HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella) are other common bacterial culprits. Fungal endocarditis, primarily caused by Candida species, is rare but associated with a poor prognosis.

Several risk factors predispose individuals to IE, including:
- Congenital heart diseases (e.g., bicuspid aortic valve, ventricular septal defect)
- Prosthetic heart valves
- Previous history of infective endocarditis
- Rheumatic heart disease
- Intravenous drug use
- Immunosuppression
- Poor dental hygiene and invasive dental procedures
- Presence of indwelling intravascular devices

Pathogenesis: The development of infective endocarditis involves a complex interplay between host factors and microbial virulence. Endothelial injury, either from turbulent blood flow or direct trauma, promotes the deposition of platelets and fibrin, creating a nidus for bacterial adherence. Transient or persistent bacteremia, resulting from invasive procedures, intravenous drug use, or mucosal injury, allows pathogens to colonize the injured endocardium. The bacteria evade host defenses and proliferate within vegetations composed of platelets, fibrin, and microorganisms. These vegetations can lead to valvular destruction, systemic embolization, and immune complex deposition, contributing to the diverse clinical manifestations of the disease.

Clinical Features: The clinical presentation of infective endocarditis is highly variable, ranging from subacute to fulminant illness. Common symptoms include:
- Persistent fever and chills
- Fatigue and malaise
- Weight loss
- Night sweats
- New or changing heart murmur
- Petechiae (small, non-blanching red spots)
- Splinter hemorrhages (linear hemorrhages under the fingernails)
- Osler nodes (painful, red nodules on fingers and toes)
- Janeway lesions (painless, erythematous macules on palms and soles)
- Roth spots (retinal hemorrhages with pale centers)

Complications such as embolic events (stroke, renal infarction), heart failure due to valvular damage, and septicemia are common, underscoring the importance of early diagnosis and intervention.

Diagnostic Evaluation: The diagnosis of infective endocarditis requires a combination of clinical suspicion, microbiological evidence, and imaging findings. The Modified Duke Criteria are widely used and incorporate major and minor criteria. Major criteria include:
- Positive blood cultures with typical IE organisms
- Evidence of endocardial involvement on echocardiography (vegetation, abscess, new dehiscence of prosthetic valve)

Minor criteria include:
- Predisposing heart condition or intravenous drug use
- Fever ≥38°C
- Vascular phenomena (arterial emboli, septic pulmonary infarcts, Janeway lesions)
- Immunologic phenomena (Osler nodes, Roth spots, rheumatoid factor)
- Positive blood cultures not meeting major criteria

Transesophageal echocardiography (TEE) is more sensitive than transthoracic echocardiography (TTE) and is preferred in high-risk patients. Laboratory investigations, including complete blood count, inflammatory markers, renal and liver function tests, and urinalysis, aid in assessing disease severity and complications.

Management: Effective management of infective endocarditis requires prompt initiation of targeted antimicrobial therapy, guided by blood culture results and susceptibility testing. Empiric therapy typically includes a combination of vancomycin and ceftriaxone until culture results are available. The duration of antibiotic therapy ranges from 4 to 6 weeks, depending on the causative organism, site of infection, and presence of prosthetic material.

Surgical intervention is indicated in approximately 25-50% of cases and is warranted in the following situations:
- Heart failure due to valvular dysfunction
- Uncontrolled infection despite appropriate antibiotic therapy
- Recurrent systemic embolization
- Large vegetations (>10 mm)
- Prosthetic valve endocarditis with dehiscence or obstruction

A multidisciplinary team approach involving cardiologists, infectious disease specialists, and cardiothoracic surgeons is essential to optimize patient outcomes.

Prevention: Preventive strategies focus on reducing the risk of bacteremia and minimizing the likelihood of microbial colonization of the endocardium. The American Heart Association recommends antibiotic prophylaxis before invasive dental, gastrointestinal, or genitourinary procedures in high-risk individuals, including those with prosthetic heart valves, previous history of infective endocarditis, certain congenital heart diseases, and cardiac transplant recipients with valvulopathy.

Good oral hygiene, regular dental care, and avoidance of intravenous drug use are crucial in preventing IE. Healthcare providers should also minimize the use of intravascular devices and ensure aseptic techniques during invasive procedures.